Clinical Trials Logo

Adult Giant Cell Glioblastoma clinical trials

View clinical trials related to Adult Giant Cell Glioblastoma.

Filter by:

NCT ID: NCT01234805 Terminated - Adult Glioblastoma Clinical Trials

Yoga Therapy in Treating Patients With Malignant Brain Tumors

Start date: December 2010
Phase: N/A
Study type: Interventional

This clinical trial studies yoga therapy in treating patients with malignant brain tumors. Yoga therapy may improve the quality of life of patients with brain tumors

NCT ID: NCT01234740 Completed - Adult Glioblastoma Clinical Trials

Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases

Start date: December 2010
Phase: Phase 1
Study type: Interventional

RATIONALE: Bafetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This clinical trial studies bafetinib in treating patients with recurrent high-grade glioma or brain metastases.

NCT ID: NCT01189240 Terminated - Adult Glioblastoma Clinical Trials

RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma

Start date: December 2010
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial is studying the side effects and the best dose of RO4929097 to see how well it works when given together with bevacizumab compared to bevacizumab alone in treating patients with progressive or recurrent malignant glioma. RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving RO4929097 together with bevacizumab may kill more tumor cells.

NCT ID: NCT01172964 Completed - Adult Glioblastoma Clinical Trials

A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas

Start date: August 2010
Phase: Phase 1
Study type: Interventional

RATIONALE: Genetically-modified neural stem cells (NSCs) that convert 5-fluorocytosine (5-FC) into the chemotherapy agent 5-FU (fluorouracil) at sites of tumor in the brain may be an effective treatment for glioma. PURPOSE: This clinical trial studies genetically-modified NSCs and 5-FC in patients undergoing surgery for recurrent high-grade gliomas.

NCT ID: NCT01165632 Active, not recruiting - Adult Glioblastoma Clinical Trials

Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma

Start date: July 26, 2010
Phase: Early Phase 1
Study type: Interventional

RATIONALE: New imaging procedures, such as fluorine F 18 fluorodopa-labeled PET scan, may help in guiding surgery and radiation therapy and allow doctors to plan better treatment. PURPOSE: This clinical trial studies fluorine F 18 fluorodopa-labeled PET scan in planning surgery and radiation therapy in treating patients with newly diagnosed high- or low-grade malignant glioma

NCT ID: NCT01148966 Terminated - Adult Glioblastoma Clinical Trials

Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain Tumors

Start date: June 2010
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of aminolevulinic acid during surgery in treating patients with malignant brain tumors. Aminolevulinic acid becomes active when it is exposed to a certain kind of light and may help doctors find and remove tumor cells during surgery

NCT ID: NCT01131234 Completed - Clinical trials for Stage IV Breast Cancer

Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors

Start date: May 2010
Phase: Phase 1
Study type: Interventional

This phase I clinical trial is studying the side effects and best dose of giving gamma-secretase inhibitor RO4929097 and cediranib maleate together in treating patients with advanced solid tumors. Gamma-secretase inhibitor RO4929097 and cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate also may stop the growth of tumor cells by blocking blood flow to the tumor.

NCT ID: NCT01122901 Active, not recruiting - Adult Glioblastoma Clinical Trials

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma

Start date: December 2010
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well gamma-secretase/Notch signalling pathway inhibitor RO4929097 works in treating patients with recurrent or progressive glioblastoma. Gamma-secretase/Notch signalling pathway inhibitor RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01122888 Terminated - Adult Glioblastoma Clinical Trials

Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme

Start date: December 2009
Phase: Phase 1
Study type: Interventional

This clinical trial is studying how well giving cilengitide together with sunitinib malate works in treating patients with advanced solid tumors or glioblastoma multiforme. Cilengitide and sunitinib malate may stop the growth of tumor cells by blocking blood flow to the tumor. Giving cilengitide together with sunitinib malate may kill more tumor cells. Studying samples of blood in the laboratory from patients receiving cilengitide and sunitinib malate may help doctors understand the effect of these drugs on biomarkers.

NCT ID: NCT01119599 Completed - Adult Glioblastoma Clinical Trials

RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma

Start date: May 2010
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of gamma-secretase/Notch signalling pathway inhibitor RO4929097 (RO4929097) when given together with temozolomide and radiation therapy in treating patients with newly diagnosed malignant glioma. Enzyme inhibitors, such as gamma-secretase/Notch signalling pathway inhibitor RO4929097, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving gamma-secretase/Notch signalling pathway inhibitor RO4929097 together with temozolomide and radiation therapy may kill more tumor cells.